ArticleBritish journal of clinical pharmacology2019
Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.
Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.International journal of antimicrobial agents · 2022Trial
- A dynamic pharmacometric framework defining the relationship between ivermectin exposure and mosquito lethality.Scientific reports · 2026Article
- Variations in Plasma Levels of Orally Administered Ivermectin Could Hamper Its Potential Drug Repositioning: Results of a Bioequivalence Study in Mexican Population.Pharmaceuticals (Basel, Switzerland) · 2025Article
- In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever.CPT: pharmacometrics & systems pharmacology · 2024Article
- Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kg.Pharmaceutics · 2024Article
- Ivermectin therapy for young children with scabies infection: a multicentre phase 2 non-randomized trial.The Lancet regional health. Western Pacific · 2024Article
- Ivermectin resistance mechanisms in ectoparasites: a scoping review.Parasitology research · 2024Article
- Article
- Review
- Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania.CPT: pharmacometrics & systems pharmacology · 2023Article
- Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru.Parasite epidemiology and control · 2023Review
- Dried Blood Spots-A Platform for Therapeutic Drug Monitoring (TDM) and Drug/Disease Response Monitoring (DRM).European journal of drug metabolism and pharmacokinetics · 2023Review
- Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes.Malaria journal · 2023Article
- Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis.PLoS neglected tropical diseases · 2023Article
- Successful management of poisoning with ivermectin (Mectizan) in the Obala health district (Centre Region, Cameroon): a case report.Journal of medical case reports · 2023Article
- STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.Current research in translational medicine · 2021Review
- Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol.Pathogens (Basel, Switzerland) · 2021Article
- Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action.Molecules (Basel, Switzerland) · 2021Review
- Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.British journal of clinical pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe anthelminthic ivermectin is receiving new attention as it is being repurposed for new indications such as mass drug administrations for the treatment of scabies or in malaria vector control. As its pharmacokinetics are still poorly understood, we aimed to characterize the population pharmacokinetics of ivermectin in plasma and dried blood spots (DBS), a sampling method better suited to field trials, with special focus on the influence of body composition and enterohepatic circulation.
methodsWe performed a clinical trial in 12 healthy volunteers who each received a single oral dose of 12 mg ivermectin, and collected peripheral venous and capillary DBS samples. We determined ivermectin concentrations in plasma and DBS by liquid chromatography tandem mass spectrometry using a fully automated and scalable extraction system for DBS sample processing. Pharmacokinetic data were analysed using non-linear mixed effects modelling.
resultsA two-compartment model with a transit absorption model, first-order elimination, and weight as an influential covariate on central volume of distribution and clearance best described the data. The model estimates (inter-individual variability) for a 70 kg subject were: apparent population clearance 7.7 (25%) l h
conclusionThe model accurately depicts population pharmacokinetics of plasma and DBS concentrations over time for oral ivermectin. The proposed analytical workflow is scalable and applicable to the requirements of mass drug administrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.